Ramucirumab plus FOLFIRI or irinotecan as second-line treatment for patients with gastroesophageal adenocarcinoma: a review and meta-analysis of an emerging option

Benutzer: Gast

Titel:: Ramucirumab plus FOLFIRI or irinotecan as second-line treatment for patients with gastroesophageal adenocarcinoma: a review and meta-analysis of an emerging option
Dokumenttyp:: Zeitschriftenaufsatz
Autor(en):: Park, Haeseong ; Klempner, Samuel J. ; Chao, Joseph ; Wainberg, Zev A. ; Lukanowski, Mariusz ; Chenji, Suresh ; Bourke, Shannon ; Chatterjee, Anindya ; Lorenzen, Sylvie
Stichworte:: Oncology ; ramucirumab ; gastroesophageal adenocarcinoma ; second-line ; irinotecan ; FOLFIRI
Zeitschriftentitel:: Frontiers in Oncology
Jahr:: 2024
Band / Volume:: 14
Volltext / DOI:: doi:10.3389/fonc.2024.1419338
Verlag / Institution:: Frontiers Media S.A.
E-ISSN:: 2234-943X
Publikationsdatum:: 13.08.2024
CC-Lizenz:: by, https://creativecommons.org/licenses/by/4.0

BibTeX

Vorkommen: